Sugi Predict

Sugi Predict / Compounds / SCHEMBL42712

SCHEMBL42712

SCHEMBL42712

C[C@]12CCC(=O)C=C1C(=O)C[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 18/20 1.00
▸ ALDH1A1 P00352 2/20 0.64
▸ LMNA P02545 2/20 0.64
▸ SHBG P04278 2/20 0.64
▸ SERPINA6 P08185 2/20 0.64
▸ MAPK1 P28482 2/20 0.64
▸ HSD17B3 P37058 2/20 0.64
▸ SNCA P37840 2/20 0.64
▸ BLM P54132 2/20 0.64
▸ PMP22 Q01453 2/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.64
▸ NPSR1 Q6W5P4 2/20 0.64
▸ HSD17B10 Q99714 2/20 0.64
▸ TSHR P16473 1/20 0.64
▸ SRD5A1 P18405 1/20 0.60
▸ SRD5A2 P31213 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2600419 1.00 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL42713 1.00 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL3275185 0.87 CYP19A1 (0.78) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL7097095 0.87 CYP19A1 (0.78) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL6821320 0.87 CYP19A1 (0.78) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL349057 0.86 CYP19A1 (0.76) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL349056 0.86 CYP19A1 (0.76) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL10187417 0.86 CYP19A1 (0.76) CYP19A1ALDH1A1LMNASHBGSERPINA6
SCHEMBL7649810 0.86 CYP19A1 (0.75) CYP19A1
SCHEMBL10528769 0.84 CYP19A1 (1.00) CYP19A1ALDH1A1LMNASHBGSERPINA6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 813 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260103461-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF OLEMA PHARMACEUTICALS INC (US) 2026-04-16 — — US claimed
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 — — EP claimed
EP-4573091-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF Olema Pharmaceuticals, Inc. (US) 2025-06-25 — — EP claimed
EP-4573092-A1 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER Olema Pharmaceuticals, Inc. (US) 2025-06-25 — — EP claimed
WO-2025122502-A1 METHODS FOR TREATING HR-POSITIVE HER2-NEGATIVE BREAST CANCER FOUNDATION MEDICINE, INC. (US) 2025-06-12 — — WO claimed
WO-2025122504-A1 ESR1 MUTATIONS, ESR1 CO-OCCURRING MUTATIONS, AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-06-12 — — WO claimed
WO-2025122500-A1 ESR1 GENE FUSIONS AND USES THEREOF FOUNDATION MEDICINE, INC. (US) 2025-06-12 — — WO claimed
CN-119187554-A High-entropy alloy slurry for vacuum cladding and preparation method of high-entropy alloy coating thereof 六盘山实验室 2024-12-27 — — CN claimed
US-12116638-B2 Estrogen receptor mutations and uses thereof FOUNDATION MEDICINE, INC. (US) 2024-10-15 — — US claimed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 — — WO claimed
WO-2008127605-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING CALCITONIN AND AN AROMATASE INHIBITOR MEDITRINA PHARMACEUTICALS, INC. (US) 2008-10-23 — — WO claimed
WO-2008042508-A1 GRP78 AS A PREDICTOR OF RESPONSIVENESS TO THERAPEUTIC AGENTS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2008-04-10 — — WO claimed
US-20050059646-A1 Use of 4-androstene-3,6,17-trione to elevate testosterone levels and the testosterone/estrogen ratio in males PROVIANT TECHNOLOGY INC. (US) 2005-03-17 — — US claimed
US-20050049231-A1 Local delivery of aromatase inhibitor using intravaginal device; estrogen dependent proliferative disorders of uterus; minimal side effects, longer term treatment, variable dosage ARES TRADING, S.A. (CH) 2005-03-03 — — US claimed
EP-1423165-A2 INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS Metris Therapeutics Limited (GB) 2004-06-02 — — EP claimed
US-6696432-B1 SYNERGYSTIC MIXTURES OF PRASTERONE, PREFERENTIAL ENZYME INHIBITORS SUCH AS FORMESTANE, TESTOLACTONE OR VOROZOLE AND CARRIERS, ADMINISTERED FOR PROPHYLAXIS OF HYPOANDROGENISM SCHERING AKTIENGESELLSCHAFT (DE) 2004-02-24 — — US claimed
WO-2003015872-A2 INTRAVAGINAL ADMINISTRATION OF AN AROMATASE INHIBITOR FOR THE TREATMENT OF OESTROGEN-DEPENDENT PROLIFERATIVE DISORDERS METRIS THERAPEUTICS LIMITED (GB) 2003-02-27 — — WO claimed
US-5733902-A Compounds having antiprogestational and anti-estrogenic activities for the treatment of hormone-dependent tumors SCHERING AKTIENGESELLSCHAFT (DE) 1998-03-31 — — US claimed
US-4598072-A Combinations of an aromatase-inhibitor and an antiandrogen for prophylaxis and/or treatment of benign prostatic hyperplasia SCHERING AKTIENGESELLSCHAFT (DE) 1986-07-01 — — US claimed
US-4596797-A Urogenital disorders SCHERING AKTIENGESELLSCHAFT (DE) 1986-06-24 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260103461-A1 ESTROGEN RECEPTOR MODULATORS AND USES THEREOF ESRRA, GPER1, ESR2 CYP19A1 12/4885ALDH1A1 1137/4885LMNA 3709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.